Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases
Purpose: Finasteride and dutasteride are used to treat benign prostatic hyperplasia (BPH) and reduce the risk of developing prostate cancer. Finasteride blocks only the type 2 form of 5-alpha-reductase, whereas dutasteride blocks both type 1 and 2 forms of the enzyme. Previous studies suggest the...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Society for Sexual Medicine and Andrology
2025-01-01
|
| Series: | The World Journal of Men's Health |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841561203000737792 |
|---|---|
| author | Dae Yul Yang Won-Woo Seo Rae Woong Park Sang Youl Rhee Jae Myung Cha Yoon Soo Hah Chang Won Jeong Kyung-Jin Kim Hyeon-Jong Yang Do Kyung Kim Ji Yong Ha |
| author_facet | Dae Yul Yang Won-Woo Seo Rae Woong Park Sang Youl Rhee Jae Myung Cha Yoon Soo Hah Chang Won Jeong Kyung-Jin Kim Hyeon-Jong Yang Do Kyung Kim Ji Yong Ha |
| author_sort | Dae Yul Yang |
| collection | DOAJ |
| description | Purpose: Finasteride and dutasteride are used to treat benign prostatic hyperplasia (BPH) and reduce the risk of developing prostate
cancer. Finasteride blocks only the type 2 form of 5-alpha-reductase, whereas dutasteride blocks both type 1 and 2 forms
of the enzyme. Previous studies suggest the possibility that dutasteride may be superior to finasteride in preventing prostate cancer.
We directly compared the effects of finasteride and dutasteride on the risk of prostate cancer in patients with BPH using a
pooled analysis of 15 real-world databases.
Materials and Methods: We conducted a multicenter, cohort study of new-users of finasteride and dutasteride. We include patients
who were prescribed 5 mg finasteride or dutasteride for the first time to treat BPH and had at least 180 days of prescription.
We excluded patients with a history of prostate cancer or a prostate-specific antigen level ≥ 4 ng/mL before the study drug
prescription. Cox regression analysis was performed to examine the hazard ratio (HR) for prostate cancer after propensity score
(PS) matching.
Results: A total of 8,284 patients of new-users of finasteride and 8,670 patients of new-users of dutasteride were included across
the 15 databases. In the overall population, compared to dutasteride, finasteride was associated with a lower risk of prostate
cancer in both on-treatment and intent-to-treat time-at-risk periods. After 1:1 PS matching, 4,897 patients using finasteride and
4,897 patients using dutasteride were enrolled in the present study. No significant differences were observed for risk of prostate
cancer between finasteride and dutasteride both on-treatment (HR=0.66, 95% confidence interval [CI]: 0.44–1.00; p=0.051)
and intent-to-treat time-at-risk periods (HR=0.87, 95% CI: 0.67–1.14; p=0.310).
Conclusions: Using real-world databases, the present study demonstrated that dutasteride was not associated with a lower risk
of prostate cancer than finasteride in patients with BPH. |
| format | Article |
| id | doaj-art-9e69cf2de4fa49779664b14d4e22d36a |
| institution | Kabale University |
| issn | 2287-4208 2287-4690 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Korean Society for Sexual Medicine and Andrology |
| record_format | Article |
| series | The World Journal of Men's Health |
| spelling | doaj-art-9e69cf2de4fa49779664b14d4e22d36a2025-01-03T04:48:34ZengKorean Society for Sexual Medicine and AndrologyThe World Journal of Men's Health2287-42082287-46902025-01-0143118819610.5534/wjmh.230327Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world DatabasesDae Yul Yang0https://orcid.org/0000-0002-7331-302XWon-Woo Seo1https://orcid.org/0000-0002-4406-5485Rae Woong Park2https://orcid.org/0000-0003-4989-3287Sang Youl Rhee3https://orcid.org/0000-0003-0119-5818Jae Myung Cha4https://orcid.org/0000-0001-9403-230XYoon Soo Hah5https://orcid.org/0000-0001-6424-4619Chang Won Jeong6https://orcid.org/0000-0002-9305-4686Kyung-Jin Kim7https://orcid.org/0000-0002-5796-3284Hyeon-Jong Yang8https://orcid.org/0000-0002-7287-4300Do Kyung Kim9https://orcid.org/0000-0002-3696-8756Ji Yong Ha10https://orcid.org/0000-0001-9011-7007Department of Urology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, SeoulDepartment of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, SeoulDepartment of Biomedical Informatics, Ajou University School of Medicine, SuwonDepartment of Endocrinology and Metabolism, Kyung Hee University College of Medicine, SeoulDepartment of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, SeoulDepartment of Urology, Daegu Catholic University School of Medicine, DaeguCentral Research Center of Biomedical Research Institute, Wonkwang University Hospital, IksanDepartment of Internal Medicine, Ewha Womans University Medical Center, Ewha Womans University School of Medicine, SeoulDepartment of Pediatrics, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, SeoulDepartment of Urology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, SeoulDepartment of Urology, Keimyung University Dongsan Hospital, DaeguPurpose: Finasteride and dutasteride are used to treat benign prostatic hyperplasia (BPH) and reduce the risk of developing prostate cancer. Finasteride blocks only the type 2 form of 5-alpha-reductase, whereas dutasteride blocks both type 1 and 2 forms of the enzyme. Previous studies suggest the possibility that dutasteride may be superior to finasteride in preventing prostate cancer. We directly compared the effects of finasteride and dutasteride on the risk of prostate cancer in patients with BPH using a pooled analysis of 15 real-world databases. Materials and Methods: We conducted a multicenter, cohort study of new-users of finasteride and dutasteride. We include patients who were prescribed 5 mg finasteride or dutasteride for the first time to treat BPH and had at least 180 days of prescription. We excluded patients with a history of prostate cancer or a prostate-specific antigen level ≥ 4 ng/mL before the study drug prescription. Cox regression analysis was performed to examine the hazard ratio (HR) for prostate cancer after propensity score (PS) matching. Results: A total of 8,284 patients of new-users of finasteride and 8,670 patients of new-users of dutasteride were included across the 15 databases. In the overall population, compared to dutasteride, finasteride was associated with a lower risk of prostate cancer in both on-treatment and intent-to-treat time-at-risk periods. After 1:1 PS matching, 4,897 patients using finasteride and 4,897 patients using dutasteride were enrolled in the present study. No significant differences were observed for risk of prostate cancer between finasteride and dutasteride both on-treatment (HR=0.66, 95% confidence interval [CI]: 0.44–1.00; p=0.051) and intent-to-treat time-at-risk periods (HR=0.87, 95% CI: 0.67–1.14; p=0.310). Conclusions: Using real-world databases, the present study demonstrated that dutasteride was not associated with a lower risk of prostate cancer than finasteride in patients with BPH.dutasteridefinasterideprostatic hyperplasiaprostatic neoplasms |
| spellingShingle | Dae Yul Yang Won-Woo Seo Rae Woong Park Sang Youl Rhee Jae Myung Cha Yoon Soo Hah Chang Won Jeong Kyung-Jin Kim Hyeon-Jong Yang Do Kyung Kim Ji Yong Ha Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases The World Journal of Men's Health dutasteride finasteride prostatic hyperplasia prostatic neoplasms |
| title | Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases |
| title_full | Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases |
| title_fullStr | Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases |
| title_full_unstemmed | Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases |
| title_short | Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases |
| title_sort | comparison of finasteride and dutasteride on risk of prostate cancer in patients with benign prostatic hyperplasia a pooled analysis of 15 real world databases |
| topic | dutasteride finasteride prostatic hyperplasia prostatic neoplasms |
| work_keys_str_mv | AT daeyulyang comparisonoffinasterideanddutasterideonriskofprostatecancerinpatientswithbenignprostatichyperplasiaapooledanalysisof15realworlddatabases AT wonwooseo comparisonoffinasterideanddutasterideonriskofprostatecancerinpatientswithbenignprostatichyperplasiaapooledanalysisof15realworlddatabases AT raewoongpark comparisonoffinasterideanddutasterideonriskofprostatecancerinpatientswithbenignprostatichyperplasiaapooledanalysisof15realworlddatabases AT sangyoulrhee comparisonoffinasterideanddutasterideonriskofprostatecancerinpatientswithbenignprostatichyperplasiaapooledanalysisof15realworlddatabases AT jaemyungcha comparisonoffinasterideanddutasterideonriskofprostatecancerinpatientswithbenignprostatichyperplasiaapooledanalysisof15realworlddatabases AT yoonsoohah comparisonoffinasterideanddutasterideonriskofprostatecancerinpatientswithbenignprostatichyperplasiaapooledanalysisof15realworlddatabases AT changwonjeong comparisonoffinasterideanddutasterideonriskofprostatecancerinpatientswithbenignprostatichyperplasiaapooledanalysisof15realworlddatabases AT kyungjinkim comparisonoffinasterideanddutasterideonriskofprostatecancerinpatientswithbenignprostatichyperplasiaapooledanalysisof15realworlddatabases AT hyeonjongyang comparisonoffinasterideanddutasterideonriskofprostatecancerinpatientswithbenignprostatichyperplasiaapooledanalysisof15realworlddatabases AT dokyungkim comparisonoffinasterideanddutasterideonriskofprostatecancerinpatientswithbenignprostatichyperplasiaapooledanalysisof15realworlddatabases AT jiyongha comparisonoffinasterideanddutasterideonriskofprostatecancerinpatientswithbenignprostatichyperplasiaapooledanalysisof15realworlddatabases |